
Selank
Synthetic analog of the immunoglobulin G-associated tetrapeptide tuftsin. Developed at the Institute of Molecular Genetics, Russian Academy of Sciences.
Quantity
Bundle & Save
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.
Selank — Key Data
A snapshot of published research on Selank. Each figure links to the literature summarized below.
How Selank Works
Selank is a synthetic tuftsin analog developed at the Russian Academy of Sciences. Its anxiolytic effects rival benzodiazepines without sedation, dependence, or withdrawal. The peptide achieves 92.8% intranasal bioavailability with blood detection within 30 seconds and brain penetration within minutes via sensory nerves bypassing the blood-brain barrier. For research use only.
Discovered ~1990s80+ publicationsInstitute of Molecular Genetics, Russian Academy of Sciences
- 01
GABAergic Modulation
Primary- r = 0.86 correlation with GABA gene expression changes
- 45 of 77 neurotransmission genes modified at 1 hour
- 95% of altered genes increased at 3 hours (rebound upregulation)
- 02
Anxiolytic Pathway
Primary- Comparable efficacy to phenazepam and medazepam (benzodiazepines)
- Zero sedation, zero dependence, zero withdrawal
- Anxiolytic effect persists 1 week after last dose
- 03
Immune / Cytokine Regulation
Secondary- Normalized IL-1beta, IL-6, TNF-alpha under stress conditions
- Restored CD4+/CD8+ T-cell ratios in anxiety patients
- Enhanced NK cell activity in suppressed individuals
What the Studies Show
Peer-reviewed outcomes from published Selank research.
0
Rapid responders (40% of patients) in a 20-patient GAD study. 2,700 mcg/day intranasal. p < 0.01. Conventional responders reached HAM-A 6.2 by Day 14.
European Psychiatry P-1114Additional Clinical Outcomes
- 0Zozulya et al., 2008
60 patients with anxiety disorders. Selank vs phenazepam showed comparable anxiolytic effect with zero sedation, zero dependence, zero withdrawal.
- 0Volkova et al., 2016
Hypocretin (orexin) gene showed the most dramatic rebound at 3 hours. Selank-specific effect not seen with GABA alone.
Anxiolytic Comparison
60 patients with anxiety disorders (Zozulya et al., 2008)
Research Applications
Reported areas of investigation across the Selank literature.
- 01ANXIOLYTIC
Rapid Anxiety Reduction
HAM-A score dropped from 20.3 to 7.0 in just 3 days in 40% of patients. Remaining patients reached HAM-A 6.2 by Day 14.
- Rapid responders
- 40% of patients
- HAM-A at Day 3 (rapid)
- 7.0
- HAM-A at Day 14 (all)
- 6.2
Study finding. 20-patient GAD study. 2,700 mcg/day intranasal. p < 0.01 for rapid responders.
European Psychiatry P-1114 - 02GENE MODULATION
Broad Neurotransmission Regulation
Modified 45 of 77 neurotransmission genes at 1 hour, with 95% of altered genes showing increased expression at 3 hours.
- Genes modified (1h)
- 45 of 77
- Genes increased (3h)
- 95%
- Hcrt rebound
- 128.3-fold
Study finding. Hypocretin (orexin) gene showed the most dramatic rebound at 3 hours, a Selank-specific effect not seen with GABA alone.
Volkova et al., 2016 - 03IMMUNE REGULATION
Cytokine Normalization Under Stress
Normalized IL-1beta, IL-6, and TNF-alpha under stress conditions while restoring CD4+/CD8+ T-cell ratios in anxiety patients.
- Cytokines normalized
- IL-1b, IL-6, TNF-a
- T-cell ratio
- Restored
- NK cell activity
- Enhanced
Study finding. Dual anxiolytic-immunomodulatory action suggests a neuro-immune feedback mechanism.
Reported Observations
- Approved pharmaceutical in Russia since 2009
- Zero sedation, zero dependence, zero withdrawal in all trials
- Enhances diazepam effects when combined (may increase GABA_A receptor affinity)
This summary reflects observations from published peer-reviewed research. It is not a comprehensive safety assessment. Researchers should review primary literature before designing protocols. For Research Use Only.
Compound Profile
What Is Selank?
Stability Information
- Protect from light
- Avoid repeated freeze-thaw cycles
- Store in original sealed container
Lyophilized (powder)
up to 2 years
Reconstituted
up to 30 days
Working solution
Use within 24 hours
References
Uchakina et al., 2008
These references are provided for informational purposes. Kern is not affiliated with the authors or institutions listed above.
Related Products
Important Notice — Please Read
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products we offer are not intended to diagnose, treat, cure, or prevent any disease. The peptides sold on this website are intended for research use only. The buyer is responsible for adhering to all local laws and regulations. Kern is not a pharmacy and does not provide medical advice or prescriptions. They are not for human consumption, are not FDA approved, and are not supplements or pharmaceutical drugs. The information provided on this website is for informational purposes and not a substitute for professional medical advice, diagnosis, or treatment. If you have questions or concerns about your health, please talk to your doctor. This site is an advertisement for education, research peptides, and not any specific medication. By purchasing from Kern, you confirm that you are a qualified researcher purchasing these compounds for legitimate in vitro or laboratory research purposes only. You must be 21 years of age or older to purchase.




